Akers Biosciences' stock soars 29% on merger deal
The combined company will be based in Baltimore and focus on developing treatments for autoimmune and age-related diseases.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: John George Source Type: news